Level D· Scientific groundwork from lab and animal studiesNarrative ReviewEurope PMC

Inflammation, autophagy, and obesity: common features in the pathogenesis of pancreatitis and pancreatic cancer

Gukovsky I., Li N., Todoric J., Gukovskaya A., Karin M.

Narrative Review, published in Gastroenterology (2013) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Narrative Review
Journal
Gastroenterology (2013)
Reported sample size
—
Source database
Europe PMC
PMID
23622129
PMCID
PMC3786712
DOI
10.1053/j.gastro.2013.02.007
Citations
266

Abstract (original English)

Inflammation and autophagy are cellular defense mechanisms. When these processes are deregulated (deficient or overactivated) they produce pathologic effects, such as oxidative stress, metabolic impairments, and cell death. Unresolved inflammation and disrupted regulation of autophagy are common features of pancreatitis and pancreatic cancer. Furthermore, obesity, a risk factor for pancreatitis and pancreatic cancer, promotes inflammation and inhibits or deregulates autophagy, creating an environment that facilitates the induction and progression of pancreatic diseases. However, little is known about how inflammation, autophagy, and obesity interact to promote exocrine pancreatic disorders. We review the roles of inflammation and autophagy, and their deregulation by obesity, in pancreatic diseases. We discuss the connections among disordered pathways and important areas for future research.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
PancreasAnimalsHumansPancreatic NeoplasmsPancreatitisObesityInflammationInflammation MediatorsRisk FactorsSignal Transduction

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.